Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre...

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
• Tramiprosate (homotaurine) is being investigated for its potential to slow AD progression.

Purpose of the Study:

• To evaluate the clinical efficacy, safety, and disease-modification effects of tramiprosate in patients with mild-to-moderate AD.
• To assess the impact of tramiprosate on cognitive decline and brain structure changes.

Main Methods:

• A 78-week, double-blind, placebo-controlled, randomized trial involving 1,052 patients with mild-to-moderate AD.
• Patients received placebo, tramiprosate 100 mg, or tramiprosate 150 mg twice daily.
• Cognitive function (ADAS-cog, CDR-SB) and hippocampus volume (MRI) were assessed.

Main Results:

• Planned analyses revealed no statistically significant differences in clinical efficacy between tramiprosate and placebo groups.
• Post-hoc analyses indicated a significant reduction in hippocampus volume loss in tramiprosate groups (P=0.035 for 100 mg, P=0.009 for 150 mg).
• A trend towards slower cognitive decline (ADAS-cog) was observed, but not on CDR-SB; adverse event rates were similar across groups.

Conclusions:

• Tramiprosate did not demonstrate significant clinical efficacy in slowing cognitive decline in mild-to-moderate AD based on primary analyses.
• Post-hoc findings suggest a potential disease-modifying effect by reducing hippocampus volume loss.
• Interpreting these results requires consideration of outcome measure limitations and disease heterogeneity.